Amelioration of bleomycin-induced pulmonary injury by cyclosporin A.
This study evaluated the effect of cyclosporin-A (CyA), a potent immunosuppressive drug, on Bleomycin (Bleo)-induced pulmonary inflammation in hamsters. Pulmonary injury was induced by a single intratracheal (i.t.) instillation of Bleo. Four groups of 10 male Syrian hamsters each received one of four treatments: (1) i.t. Bleo and daily intraperitoneal (i.p.) injections of CyA starting 1 day before i.t. instillation of Bleo (Bleo-CyA); (2) i.t. Bleo and i.p. injections of saline (Bleo-Sal); (3) i.t. saline and i.p. CyA (Sal-CyA); (4) i.t. saline and i.p. saline (Sal-Sal). Animals were sacrificed 14 days after i.t. treatment. Lung injury was evaluated histologically, biochemically, and by analysis of bronchoalveolar lavage (BAL) fluid. Treatment of hamsters with CyA significantly ameliorated the Bleo-induced lung injury, as determined by a semiquantitative morphological index that assesses the severity and extent of the injury on a scale of 0-3. Lung hydroxyproline measurements were lower in Bleo-CyA compared to Bleo-Sal, comparable to Sal-Sal and Sal-CyA controls. The percentage of neutrophils, eosinophils, and lymphocytes in BAL fluid was higher in Bleo-Sal and Bleo-CyA animals when compared with control Sal-CyA or Sal-Sal animals. A further increase in percentage of eosinophils was observed in Bleo-CyA compared with Bleo-Sal animals (13.3 +/- 6.6% [mean +/- SE] and 3.7 +/- 2.1%, respectively, p = .0007). BAL fluid protein content was higher in Bleo-Sal compared to Sal-Sal animals, but BAL fluid protein content from Bleo-CyA was not significantly different from that of Bleo-Sal animals. These results indicate that CyA ameliorates the Bleo-induced inflammation but does not prevent leakage of plasma protein or cells into the airspaces. The increased eosinophil numbers in Bleo-CyA-treated hamsters suggests enhanced production of interleukin-4 and -5.
Lossos
I S
IS
Pulmonary Cell and Molecular Laboratory, Hadassah University Hospital, Jerusalem, Israel.
Or
R
R
Goldstein
R H
RH
Conner
M W
MW
Breuer
R
R
D000818:Animals; D001761:Bleomycin; D001835:Body Weight; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology / Q000276:immunology; D002452:Cell Count; D006224:Cricetinae; D016572:Cyclosporine / Q000097:blood / Q000494:pharmacology*; D005355:Fibrosis; D006909:Hydroxyproline / Q000032:analysis; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008168:Lung / Q000737:chemistry / Q000276:immunology* / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008647:Mesocricetus; D011506:Proteins / Q000032:analysis
D007166:Immunosuppressive Agents; D011506:Proteins; D001761:Bleomycin; D016572:Cyclosporine; D006909:Hydroxyproline